Last reviewed · How we verify
Salbutamol HFA-152a
Salbutamol HFA-152a is a short-acting beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs.
Salbutamol HFA-152a is a short-acting beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs. Used for Maintenance and relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Salbutamol HFA-152a |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Beta-2 adrenergic receptor agonist |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to beta-2 adrenergic receptors in the bronchial smooth muscle, causing bronchodilation and reducing airway resistance. This results in improved lung function and relief of symptoms in patients with asthma and COPD.
Approved indications
- Maintenance and relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Nervousness
- Headache
Key clinical trials
- A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma (PHASE3)
- A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive (PHASE1)
- A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive (PHASE1)
- Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salbutamol HFA-152a CI brief — competitive landscape report
- Salbutamol HFA-152a updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI